Amarin Corp Plcuk (AMRN) Other Non-Current Liabilities (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Other Non-Current Liabilities of $11.1 million for Q1 2026, down 4.47% YoY from $11.6 million in Q1 2025, and up 1.52% sequentially from $11.0 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Other Non-Current Liabilities across 17 years of filings, most recently posting $11.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 4.47% year-over-year to $11.1 million; the TTM figure through Mar 2026 stood at $11.1 million (down 4.47% YoY), while the FY2025 annual figure was $11.0 million, down 4.75% from the prior year.
- Other Non-Current Liabilities improved to $11.1 million in Q1 2026, from $11.0 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for AMRN reached as high as $12.0 million in Q3 2025 and fell as low as $7.2 million in Q2 2023.
- The 5-year median for Other Non-Current Liabilities is $9.3 million (2024), against an average of $9.5 million.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 81.25% — and 2023, when it slipped 25.0%.
- A 5-year view of Other Non-Current Liabilities shows it stood at $8.2 million in 2022, then climbed by 10.47% to $9.1 million in 2023, then climbed by 26.89% to $11.5 million in 2024, then declined by 4.75% to $11.0 million in 2025, then grew by 1.52% to $11.1 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $11.1 million, $11.0 million, and $12.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.12 Mn |
| Dec 31, 2025 | 10.96 Mn |
| Sep 30, 2025 | 11.96 Mn |
| Jun 30, 2025 | 11.92 Mn |
| Mar 31, 2025 | 11.64 Mn |
| Dec 31, 2024 | 11.50 Mn |
| Sep 30, 2024 | 9.47 Mn |
| Jun 30, 2024 | 9.34 Mn |
| Mar 31, 2024 | 9.20 Mn |
| Dec 31, 2023 | 9.06 Mn |
| Sep 30, 2023 | 7.27 Mn |
| Jun 30, 2023 | 7.16 Mn |
| Mar 31, 2023 | 8.61 Mn |
| Dec 31, 2022 | 8.21 Mn |
| Sep 30, 2022 | 9.70 Mn |
| Jun 30, 2022 | 7.64 Mn |
| Mar 31, 2022 | 7.49 Mn |
| Dec 31, 2021 | 7.65 Mn |
| Sep 30, 2021 | 5.35 Mn |
| Jun 30, 2021 | 5.53 Mn |